4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline

Product Overview

Welcome to our comprehensive product page for 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline, a critical pharmaceutical intermediate identified by CAS number 183377-18-1. This specialized chemical compound serves as a foundational building block in the synthesis of advanced oncology therapeutics, specifically acting as a key precursor in the manufacturing process of Erlotinib hydrochloride. Our facility is dedicated to producing high-quality intermediates that meet the rigorous demands of the global pharmaceutical supply chain. We understand the importance of consistency and purity in drug development, which is why our production protocols are designed to exceed industry standards for safety and efficacy.

Chemical Properties and Structure

From a chemical perspective, this quinazolinone derivative exhibits distinct physical and chemical properties that make it suitable for complex organic synthesis reactions. The molecular formula C14H18ClN2O5 represents a structured arrangement that facilitates specific nucleophilic substitution reactions required for downstream API production. With a molecular weight of approximately 329.76 g/mol, the compound maintains stability under controlled conditions. Our manufacturing process ensures that the density remains consistent at 1.215 g/cm3, and the boiling point is recorded at 467.8ºC at 760 mmHg. These parameters are critical for chemists planning reaction scales and purification steps during the drug development lifecycle. The refractive index of 1.51 further confirms the optical purity of the material.

Industrial Applications

The primary industrial application of this material lies within the pharmaceutical sector, specifically targeting the production of tyrosine kinase inhibitors. As an intermediate for Erlotinib, it plays a vital role in treatments for non-small cell lung cancer and pancreatic cancer. The high purity level of our product ensures that subsequent synthesis steps proceed with minimal side reactions, thereby improving the overall yield of the final active pharmaceutical ingredient. We support research and development teams as well as large-scale commercial manufacturing units with reliable supply chains. Our commitment to quality ensures that every batch contributes to the safety and efficacy of the final medicinal product used in clinical settings.

Quality Specifications

Quality assurance is the cornerstone of our operation. Each batch of 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline undergoes stringent analytical testing to verify compliance with specified parameters. The appearance is consistently maintained as a white or off-white crystalline powder, indicating high levels of crystallinity and purity. Our standard specification guarantees a purity level of greater than or equal to 99 percent, with total impurities controlled below 0.5 percent. Water content is strictly managed to remain under 0.5 percent, and residue on ignition is limited to 0.1 percent. Single impurity levels are monitored closely to ensure no individual contaminant exceeds 0.1 percent. We provide comprehensive Certificates of Analysis for every shipment.

Storage and Handling

Proper handling and storage are essential to maintain the integrity of this chemical intermediate. We recommend storing the material in a cool and dry environment within well-closed containers. It is crucial to keep the product away from moisture and strong light or heat sources to prevent degradation. Our standard packing options include 25kg cardboard drums, though we can accommodate custom packaging requirements based on customer specifications. As a global manufacturer, we offer competitive bulk pricing and robust technical support. Whether you require this intermediate for process development or commercial production, our team is ready to assist with logistics and documentation to ensure a smooth procurement experience.